Table 2.

Diagnostic sensitivity of HR-IFE, IFE, and FLC κ/λ ratio in 115 patients with systemic AL amyloidosis.

Patients with κ clones (n = 30)Patients with λ clones (n = 85)Overall population (N = 115)
No. positive% (95% CI)No. positive% (95% CI)No. positive% (95% CI)
Serum HR-IFE2583 (67–94)8499 (94–100)10995 (89–98)
Urine HR-IFE2997 (85–100)8094 (87–98)10995 (89–98)
Serum and urine HR-IFE30100 (90–100)85100 (96–100)115100 (97–100)
Semiautomated serum IFE1860 (42–76)7487 (79–93)9280 (72–87)
Semiautomated urine IFE2170 (52–84)5665 (55–75)7767 (58–75)
Semiautomated serum and urine IFE2790 (75–97)8398 (92–100)11096 (91–98)
FLC κ/λ ratio2997 (85–100)5969 (59–79)8876 (68–84)
Serum IFE + FLC κ/λ ratio30100 (90–100)8094 (87–98)11096 (91–98)
Urine IFE + FLC κ/λ ratio2997 (85–100)7791 (83–95)10692 (86–96)
Serum and urine IFE + FLC κ/λ ratio30100 (90–100)85100 (96–100)115100 (97–100)